Color Doppler Endosonography of Esophageal Varices: Signal Enhancement After Intravenous Injection of the Ultrasound Contrast Agent Levovist

Duplex Doppler endosonographic transducers have opened up new opportunities in the evaluation of blood flow in esophageal varices (1–3). A new ultrasound contrast agent, Levovist (Schering), leads to a significant improvement in the detection and enhancement of color Doppler flow signals in several organs of the gut (4,5). We present here preliminary data on the combined use of color Doppler ultrasound and the ultrasound contrast agent Levovist. We report for the first time the detection of blood flow in esophageal varices that were not previously detectable using color Doppler endosonography without a contrast agent, and signal enhancement of the blood flow signals in esophageal varices that were previously detectable using endoscopic color Doppler ultrasound.

In five patients (four men, mean age 56 years, and one woman, age 40 years) with esophageal varices (one patient with grade I, one with grade II, two patients with grade III, and one patient with grade III varices, one week after sclerotherapy), endosonographic examination was carried out using a Pentax FG32-UA endoscope. The varices were examined by B-mode first, and then with color-coded Doppler ultrasound before and after intravenous injection of Levovist (Table 1). Prior to the application of the contrast agent, color flow signals could be detected in grade III varices only. After the application of Levovist, clear color flow signals were detected under the third echo-dense layer of the esophageal wall in patients with grade I and II varices, and in one patient a perforating vein was visualized (Figure 1). Color Doppler endosonography and ultrasound contrast agents can help to visualize blood flow in esophageal perforating veins and peri-esophageal vessels more clearly, and may provide new insights into the hemodynamics of portal hypertension.

H. Ernst, G. Niesko, E.G. Hahn, N. Heyder
Dept. of Medicine I, University of Erlangen-Nuremberg, Erlangen, Germany

<table>
<thead>
<tr>
<th>Patient</th>
<th>Grade of esophageal varices</th>
<th>CDE without contrast</th>
<th>CDE and Levovist 200 mg/ml</th>
<th>CDE and Levovist 300 mg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 M. J.</td>
<td>II</td>
<td>No flow signals</td>
<td>+</td>
<td>*</td>
</tr>
<tr>
<td>2 S. G.</td>
<td>III after sclerotherapy</td>
<td>No flow signals</td>
<td>No flow signals</td>
<td>No flow signals</td>
</tr>
<tr>
<td>3 O. U.</td>
<td>II–III</td>
<td>Flow signals</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>4 D. M.</td>
<td>I</td>
<td>No flow signals</td>
<td>*</td>
<td>+</td>
</tr>
<tr>
<td>5 E. H.</td>
<td>III</td>
<td>Flow signals</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

CDE: color Doppler endosonography.
0: No enhancement of color Doppler flow signals.
*: Enhancement of color Doppler flow signals.
+*: Additional flow signals in submucosal vessels.
++: Additional flow in a perforating vein.

References
5. Schlief R, Schürmann R, Niendorf HP. 

Corresponding Author
H. Ernst, M.D.
Dept. of Medicine IV, Charité
Schumannstrasse 20/21, 10117 Berlin
Germany
Fax: +49-30-2802-8978
E-mail: ernsthe@rz.charite.hu-berlin.de